Gilead Sciences Inc. has agreed a new deal worth $5.05bn with existing partner Galapagos NV which sees the US firm increasing its stake in the Belgian biotech, although it won’t go above 30% and is still on the lookout for additional deals to swell its pipeline. Gilead will pay $3.95bn in cash upfront, and $1.1bn for an equity investment, plus additional milestones and royalties.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?